STP-705 is a Antisense RNAi Oligonucleotide owned by Sirnaomics, and is involved in 14 clinical trials, of which 2 were completed, 7 are ongoing, and 5 are planned.

STP705 acts by targeting transforming growth factor beta 1 (TGF beta 1) and cyclooxygenase-2. TGF-beta 1 is released in large quantities by degranulating platelets. It is activated from its latent complex by proteolytic and non-proteolytic mechanisms to influence wound healing from the initial insult and clot formation to the final phase of matrix deposition and remodeling. Cyclooxygenase-2 (COX-2) undergoes immediate-early up-regulation in response to an inflammatory stimulus, such as a wound. The drug candidate may act by decreasing the levels of transforming growth factor beta 1 and cyclooxygenase-2.

The revenue for STP-705 is expected to reach a total of $7.4bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the STP-705 NPV Report.

STP-705 was originated by Sirnaomics and General Research Laboratory and is currently owned by Sirnaomics.

STP-705 Overview

STP705 is under development for the treatment of cutaneous squamous cell carcinoma in situ (isSCC, Bowen's disease), facial squamous cell skin cancer in situ (isSCC), advanced liver tumor, pancreatic cancer, hepatocellular cancer, bladder cancer, basal cell carcinoma, primary sclerosing cholangitis, keloid scarless healing, skin hypertrophic scars, non-alcoholic steatohepatitis, abdominal obesity, cholangiocarcinoma and liver metastasis. The drug is administered topically as cream, through intradermal injection and intra-tumorally and subcutaneously. It is developed based on RNAi technology. It was under development for the treatment of pulmonary fibrosis,kidney fibrosis and wounds.

Sirnaomics Overview

Sirnaomics, is a healthcare service provider that discovers and develops therapeutics. The company’s products portfolio includes siRNA and niRNA. It offers product development, preclinical programs, clinical development services, and others. Sirnaomics provides its products for therapeutic programs such as lung cancer, breast cancer, organ transplantation, skin hypertrophic scars, colorectal cancer, influenza A, HPV and cervical cancer, ocular neo-vascularization, spinal cord injury, EBOLA infection, and giloblastoma, among others. The company also provides active pharmaceutical ingredients as therapeutic agents for treatment of various critical human diseases. It has its presence in the US and China. the company is headquartered in Gaithersburg, Maryland, the US.

The operating loss of the company was US$215.6 million in FY2021, compared to an operating loss of US$46.2 million in FY2020. The net loss of the company was US$213.1 million in FY2021, compared to a net loss of US$43.8 million in FY2020.

Quick View – STP-705

Report Segments
  • Innovator
Drug Name
  • STP-705
Administration Pathway
  • Intradermal
  • Intratumor
  • Subcutaneous
  • Topical
Therapeutic Areas
  • Dermatology
  • Gastrointestinal
  • Genito Urinary System And Sex Hormones
  • Metabolic Disorders
  • Oncology
  • Respiratory
Key Companies
  • Sponsor Company: Sirnaomics
  • Originator: Sirnaomics and General Research Laboratory
Highest Development Stage
  • Phase II


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.